Ozempic is getting generics as low as $15
New York Post • • business
Key Points:
- India will allow the sale of generic versions of Ozempic and Wegovy starting this weekend, following the expiration of Novo Nordisk's patent on semaglutide, potentially reducing prices by 50-60% and increasing access to these diabetes and obesity treatments.
- Other countries such as China, Brazil, Turkey, and South Africa are expected to see generic versions soon as patents expire, while Canada may not have cheaper alternatives until mid-2026.
- Novo Nordisk is responding to patent expirations by lowering prices in some markets and positioning its original drugs as premium brands to maintain competitiveness against generics.
- In the United States, patents on Ozempic and Wegovy remain in place until 2032, meaning FDA-approved generic versions
